TAK1 is an essential regulator of BMP signalling in cartilage

被引:114
|
作者
Shim, Jae-Hyuck [1 ]
Greenblatt, Matthew B. [1 ]
Xie, Min [2 ]
Schneider, Michael D. [3 ]
Zou, Weiguo [1 ]
Zhai, Bo [4 ]
Gygi, Steven [4 ]
Glimcher, Laurie H. [1 ,5 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[3] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England
[4] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
来源
EMBO JOURNAL | 2009年 / 28卷 / 14期
基金
美国国家卫生研究院;
关键词
BMP; cartilage; Smad; TAK1; TGF beta; FAMILY MEDIATOR SMAD1; TGF-BETA RECEPTOR; GROWTH-PLATE; KINASE TAK1; IN-VIVO; CHONDROCYTE DIFFERENTIATION; INDIAN-HEDGEHOG; II RECEPTOR; PATHWAYS; MICE;
D O I
10.1038/emboj.2009.162
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
TGF beta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis. To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter. Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion. This phenotype resembled that of bone morphogenetic protein receptor (BMPR) 1 and Gdf5-deficient mice. BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases. TAK1 mediates Smad1 phosphorylation at C-terminal serine residues. These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways. Our experiments reveal an essential role for TAK1 in the morphogenesis, growth, and maintenance of cartilage. The EMBO Journal (2009) 28, 2028-2041. doi: 10.1038/emboj.2009.162; Published online 18 June 2009
引用
收藏
页码:2028 / 2041
页数:14
相关论文
共 50 条
  • [41] The Yersinia enterocolitica effector YOPP inhibits host cell signalling at the level of the protein kinase TAK1 in the IL-1 signalling pathway
    Thiefes, A
    Wolf, A
    Grass, GA
    Doerrie, A
    Matsumoto, K
    Autenrieth, I
    Bohn, E
    Sakurai, H
    Niedenthal, R
    Resch, K
    Kracht, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 : 74 - 74
  • [42] TAK1 in tumor angiogenesis and bone metastasis
    Bakin, Andrei
    Safina, Alfiya
    CANCER RESEARCH, 2009, 69
  • [43] Suppression of Tak1 Promotes Prostate Tumorigenesis
    Wu, Min
    Shi, Lihong
    Cimic, Adela
    Romero, Lina
    Sui, Guangchao
    Lees, Cynthia J.
    Cline, J. Mark
    Seals, Darren F.
    Sirintrapun, Joseph S.
    McCoy, Thomas P.
    Liu, Wennuan
    Kim, Jin Woo
    Hawkins, Gregory A.
    Peehl, Donna M.
    Xu, Jianfeng
    Cramer, Scott D.
    CANCER RESEARCH, 2012, 72 (11) : 2833 - 2843
  • [45] Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines
    Larsen, Karen Colbjorn
    Spencer, Alexandra J.
    Goodman, Anna L.
    Gilchrist, Ashley
    Furze, Julie
    Rollier, Christine S.
    Kiss-Toth, Endre
    Gilbert, Sarah C.
    Bregu, Migena
    Soilleux, Elizabeth J.
    Hill, Adrian V. S.
    Wyllie, David H.
    VACCINE, 2009, 27 (41) : 5589 - 5598
  • [46] Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death
    Dave J. Augeri
    Elaine Langenfeld
    Monica Castle
    John A. Gilleran
    John Langenfeld
    Molecular Cancer, 15
  • [47] Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death
    Augeri, Dave J.
    Langenfeld, Elaine
    Castle, Monica
    Gilleran, John A.
    Langenfeld, John
    MOLECULAR CANCER, 2016, 15
  • [48] USP4 deficiency exacerbates hepatic ischaemia/reperfusion injury via TAK1 signalling
    Zhou, Jiangqiao
    Qiu, Tao
    Wang, Tianyu
    Chen, Zhongbao
    Ma, Xiaoxiong
    Zhang, Long
    Zou, Jilin
    CLINICAL SCIENCE, 2019, 133 (02) : 335 - 349
  • [49] TAK1 blockade as a therapy for retinal neovascularization
    Wang, Jiang-Hui
    Lin, Fan-Li
    Chen, Jinying
    Zhu, Linxin
    Chuang, Yu-Fan
    Tu, Leilei
    Ma, Chenkai
    Ling, Damien
    Hewitt, Alex W.
    Tseng, Ching-Li
    Shah, Manisha H.
    Bui, Bang V.
    van Wijngaarden, Peter
    Dusting, Gregory J.
    Wang, Peng-Yuan
    Liu, Guei-Sheung
    PHARMACOLOGICAL RESEARCH, 2023, 187
  • [50] Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors
    Tan, Li
    Gurbani, Deepak
    Weisberg, Ellen L.
    Jones, Douglas S.
    Rao, Suman
    Singer, William D.
    Bernard, Faviola M.
    Mowafy, Samar
    Jenney, Annie
    Du, Guangyan
    Nonami, Atsushi
    Griffin, James D.
    Lauffenburger, Douglas A.
    Westover, Kenneth D.
    Sorger, Peter K.
    Gray, Nathanael S.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (04) : 1320 - 1328